Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
about
Why do inhibitors arise in patients with haemophilia A?Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.Immune tolerance induction: recombinant vs. human-derived product.Mild hemophilia A.Inhibitors: resolving diagnostic and therapeutic dilemmas.The epidemiology of inhibitors in haemophilia A: a systematic review.Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.The epidemiology of factor VIII inhibitors.Inhibitor treatment in haemophilias A and B: inhibitor diagnosis.Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment.Risk factors for inhibitor formation in haemophilia: a prevalent case-control study.Management of dental extraction in patients with Haemophilia A and B: a report of 58 extractions.The Association Between HLA Class II Alleles and the Occurrence of Factor VIII Inhibitor in Thai Patients with Hemophilia A.Factor VIII safety: plasma-derived versus recombinant products.The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.Development and introduction of recombinant factor VIII--a clinician's experience.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceInhibitors - genetic and environmental factors.Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.The growing number of hemophilia registries: Quantity vs. quality.Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.The role of previously untreated patient studies in understanding the development of FVIII inhibitors.Why do so many haemophilia A patients develop an inhibitor?Recombinant coagulation factor products.Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia A.Investigation of porcine parvovirus among persons with hemophilia receiving Hyate:C porcine factor VIII concentrate.Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany.Inhibitor development and substitution therapy in a developing country: Turkey.Development of a factor VIII inhibitor in a newborn haemophiliac.The uptake of recombinant Factor VIII in the Netherlands.Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention.A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group.Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs.Third and fourth Workshops of the European Paediatric Network for Haemophilia Management.Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.Major surgery for a gastric cancer in a haemophilic with high inhibitor titre successfully performed by the use of recombinant FVIIa.Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors.
P2860
Q33650193-6E0C5444-3B61-4105-BEE9-D9BAB5E69E11Q33709854-F17B6C10-5757-4DF4-8BA3-5848B3F71DAEQ34117221-7C51F7B7-F340-4104-8CFC-66F0E03E3D19Q34614695-B34BC311-1053-46D8-B758-8CBD9FBBF846Q34636988-F10E56D7-80CF-4F21-9FC8-B80A47349861Q35163634-D7E00C4E-6DF3-4FAB-A329-5EEAA3C93A02Q36230842-16B5FB0A-6426-41E7-86A6-91E1BB1C3D84Q36643861-D7DC539D-55CE-436B-A4B9-BA8595CF9A90Q36661815-96BB5F06-E100-4F42-81BE-E33EA4D15728Q36661822-18E1EB82-35FD-406E-B3DB-7C7C85AF8607Q37075305-0722B40D-79C1-406B-B29F-8C4AAEDF63B9Q37325682-F3EA1E17-A3EE-480B-98A0-F90AB139A341Q37539773-92E695EB-61E6-4184-9734-2FA3138BF0A5Q37702836-D91D55C7-5505-45BB-95D9-8CB415EE2BA8Q37882787-6E32FA6E-8EF3-4D7B-89C2-5EE3D6A6C1C4Q37924970-273EC4B5-C88D-4203-8013-48483D258BDCQ38003396-1BD71D67-DD70-4036-B59B-C5768EF57676Q38101041-197A26DC-2734-4FAE-B82C-E00DD83FB346Q38206856-BCFCA5A6-C2F6-4B61-A5A0-9A5C555766BDQ38224295-71E5E9EE-14B3-4D5E-8EAE-78E011DBF4F7Q38351067-287C7935-C406-47F7-A025-007A299DC12AQ38493172-D9D4E2C2-9104-471C-8A87-667551E0F0C7Q38575475-A6FBF180-093D-4CB6-BCE0-540AEE861D10Q40466224-7D124573-76D7-4603-B6F1-4A487CBD45E5Q40978925-DA2ED581-4654-4049-A981-9058E1827BA0Q41684827-0BE09F49-F258-480B-AB8B-D21534A507F2Q43214848-6E5C0F2C-9504-4BC1-A281-E749092BE232Q44544084-6D965A67-F6DB-4E1C-B230-04932CBE11FCQ45855167-6F10F128-7607-4E7D-A56F-1491680406A7Q45855332-DAE9DAF2-2D21-4302-921C-3E75FECEDFB4Q45855857-BE303B1A-9BD4-4685-8A55-1ADC4C9F0481Q45856064-0ADB9047-ADC7-4E3D-8AC7-BF3D8652AF38Q45856532-60528B96-A88A-498C-B0EB-342656BB3F84Q45856561-CE3DED27-63B0-4FE2-A86A-E1BCF5B428C4Q45858508-6AE083FD-FBF1-4981-B52D-9863D2985BC6Q45858995-D3C51E94-BC3A-44F0-93D9-C377C763BD46Q45859168-7232B4F8-4E8F-48D0-8393-43314812CA88Q45863784-8CB846F5-3ABF-4382-8ADA-BED531EA7ADDQ45866892-4A5E3480-A83C-4774-A295-7740624B6217Q45867232-97A8D604-8001-4F9A-8E1C-95BE90ABFD02
P2860
Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
@en
Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
@nl
type
label
Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
@en
Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
@nl
prefLabel
Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
@en
Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
@nl
P2093
P1433
P1476
Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
@en
P2093
C Abildgaard
M Hilgartner
P304
P356
10.1016/0140-6736(93)91593-B
P407
P577
1993-08-01T00:00:00Z